Medical progress: Biliary tract cancers

New England Journal of Medicine

Volumn 341, Issue 18, 1999, Pages 1368-1378

  De Groen, Piet C ^a   Gores, Gregory J ^a   LaRusso, Nicholas F ^a   Gunderson, Leonard L ^a   Nagorney, David M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; GENE MUTATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; BILIARY TRACT TUMOR; CHOLANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HEPATOBILIARY SYSTEM; HUMAN; PATHOLOGY; RISK FACTOR;

BILIARY TRACT; BILIARY TRACT NEOPLASMS; CHOLANGIOGRAPHY; HUMANS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033613334     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199910283411807     Document Type: Review

References (126)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29. [Errata, CA Cancer J Clin 1998;48:192, 329.]
2. Percy C, Van Holten V, Muir C, eds. International classification of diseases for oncology. 2nd ed. Geneva: World Health Organization, 1990.
3. Albores-Saavedra J, Henson DE, Sobin LH. Histological typing of tumours of the gallbladder and extrahepatic bile ducts. 2nd ed. Berlin, Germany: Springer-Verlag, 1991.
4. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-75.
5. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features. Am J Med 1965;38:241-56.
6. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992;215:31-8.
7. Pitt HA, Dooley WC, Yeo CJ, Cameron JL. Malignancies of the biliary tree. Curr Probl Surg 1995;32:1-90.
8. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder: histologic types, stage of disease, grade, and survival rates. Cancer 1992;70:1493-7.
9. Idem. Carcinoma of the extrahepatic bile ducts: histologic types, stage of disease, grade, and survival rates. Cancer 1992;70:1498-501.
10. Tumors of the gallbladder and extrahepatic bile ducts. In: Albores-Saavedra J, Henson DE. Atlas of tumor pathology. 2nd series. Fascicle 22. Washington, D.C.: Armed Forces Institute of Pathology, 1986.
11. Tumors of the liver and intrahepatic bile ducts. In: Craig JR, Peters RL, Edmondson HA. Atlas of tumor pathology. 2nd series. Fascicle 26. Washington, D.C.: Armed Forces Institute of Pathology, 1989.
12. Segarra P, Abril V, Gil M, Ortega E, Ballester JE, Traves V. Sarcoma de Kaposi de la via biliar sin afectación cutánea en paciente con SIDA. Rev Esp Enferm Dig 1996;88:637-9.
13. O'Boyle MK. Gallbladder wall mass on sonography representing large-cell non-Hodgkin's lymphoma in an AIDS patient. J Ultrasound Med 1994;13:67-8.
14. Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997.
15. Adson MA. Carcinoma of the gallbladder. Surg Clin North Am 1973; 53:1203-16.
16. Zatonski WA, Lowenfels AB, Boyle P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997;89: 1132-8.
17. Lowenfels AB, Walker AM, Althaus DP, Townsend G, Domellof L. Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol 1989;18:50-4.
18. Ransohoff DF, Gracie WA. Treatment of gallstones. Ann Intern Med 1993;119:606-19.
19. Csendes A, Becerra M, Burdiles P, Demian I, Bancalari K, Csendes P. Bacteriological studies of bile from the gallbladder in patients with carcinoma of the gallbladder, cholelithiasis, common bile duct stones and no gallstones disease. Eur J Surg 1994;160:363-7.
20. Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the gallbladder. Eur J Cancer Prev 1997;6:557-9.
21. Strom BL, Soloway RD, Rios-Dalenz JL, et al. Risk factors for gallbladder cancer: an international collaborative case-control study. Cancer 1995;76:1747-56.
22. Dutta U, Garg PK, Kumar R, Tandon RK. Chronic salmonella typhi carrier state and cholelithiasis: cofactors in the pathogenesis of carcinoma of the gallbladder. Digestion 1998;59:Suppl 3:576. abstract.
23. Chijiiwa K, Tanaka M. Polypoid lesion of the gallbladder: indications of carcinoma and outcome after surgery for malignant polypoid lesion. Int Surg 1994;79:106-9.
24. Polk HC Jr. Carcinoma and the calcified gall bladder. Gastroenterology 1966;50:582-5.
25. Chijiiwa K, Kimura H, Tanaka M. Malignant potential of the gallbladder in patients with anomalous pancreaticobiliary ductal junction: the difference in risk between patients with and without choledochal cyst. Int Surg 1995;80:61-4.
26. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: a population-based study. Scand J Gastroenterol 1997;32:1042-5.
27. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5.
28. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995;117:146-55.
29. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21-5.
30. Callea F, Sergi C, Fabbretti G, Brisigotti M, Cozzutto C, Medicina D. Precancerous lesions of the biliary tree. J Surg Oncol Suppl 1993;3:131-3.
31. Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. Br J Surg 1996;83:1062-4.
32. Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Im J Epidemiol 1996;25:933-40.
33. Chow WH, McLaughlin JK, Menck HR, Mack TM. Risk factors for extrahepatic bile duct cancers: Los Angeles County, California (USA). Cancer Causes Control 1994;5:267-72.
34. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998;27:311-6.
35. Sanabria JR, Croxford R, Berk TC, Cohen Z, Bapat BV, Gallinger S. Familial segregation in the occurrence and severity of periampullary neoplasms in familial adenomatous polyposis. Am J Surg 1996;171:136-41.
36. Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992;102:1980-2.
37. Ekbom A, Yuen J, Karlsson BM, McLaughlin JK, Adami HO. Risk of pancreatic and periampullar cancer following cholecystectomy: a population-based cohort study. Dig Dis Sci 1996;41:387-91.
38. Hakamada K, Itoh T, Endoh M, Sasaki M. Late bile duct cancer after the manipulation of the sphincter of Oddi in the treatment of benign pancreatobiliary diseases. Digestion 1998;59:Suppl 3:577. abstract.
39. Seitz JF, Giovannini M, Wartelle C, Monges G, Dhiver C, Gastaut JA. Association d'un sarcome de Kaposi de l'ampoule de Vater et d'une cholangite sclérosante à Cryptosporidium chez un patient porteur d'un SIDA. Gastroenterol Clin Biol 1990;14:889-91.
40. Suto T, Sugai T, Nakamura S, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer 1998;82:86-95.
41. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998;29:175-80.
42. Rijken AM, van Gulik TM, Polak MM, Sturm PD, Gouma DJ, Offerhaus GJ. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 1998;68: 187-92.
43. Voravud N, Foster CS, Gilbertson JA, Sikora K, Waxman J. Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol 1989;20:1163-8.
44. Sasaki M, Nakanuma Y, Terada T, Kim YS. Biliary epithelial expression of MUC1, MUC2, MUC3 and MUC5/6 apomucins during intrahepatic bile duct development and maturation: an immunohistochemical study. Am J Pathol 1995;147:574-9.
45. Yamashita K, Yonezawa S, Tanaka S, et al. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int J Cancer 1993;55:82-91.
46. Farley DR, Weaver AL, Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995;70:425-9.
47. Liu KJ, Richter HM, Cho MJ, Jarad J, Nadimpalli V, Donahue PE. Carcinoma involving the gallbladder in elderly patients presenting with acute cholecystitis. Surgery 1997;122:748-56.
48. Ker CG, Wu CC, Chen JS, Hou MF, Lee KT, Sheen PC. A study of CEA, CA 19-9 and CA125 in biliary tract diseases. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1989;5:107-13.
49. Ker CG, Chen JS, Lee KT, Sheen PC, Wu CC. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 1991;6:505-8.
50. Sasaki M, Morita T, Hoso M, Nakanuma Y, Tanimura H. Carcinoembryonic antigen and blood group-related carbohydrate antigens in glycoproteins in human bile in hepatolithiasis. Hepatology 1996;23:258-63.
51. Körner T, Kropf J, Jaspersen D, Schorr W, Hammar C-H, Gressner AM. Fibronectin in menschlicher Galle - ein neuer Parameter zur Diagnostik maligner Gallengangsprozesse? - Eine Pilotstudie. Z Gastroenterol 1994;32:87-90.
52. Nishijima T, Nishina M, Fujiwara K. Measurement of lactate levels in serum and bile using proton nuclear magnetic resonance in patients with hepatobiliary diseases: its utility in detection of malignancies. Jpn J Clin Oncol 1997;27:13-7.
53. Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 1991;63:636-40.
54. Su WC, Chan KK, Lin XZ, et al. A clinical study of 130 patients with biliary tract cancers and periampullary tumors. Oncology 1996;53:488-93.
55. Bhargava AK, Petrelli NJ, Karna A, et al. Serum levels of cancer-associated antigen CA-195 in gastrointestinal cancers and its comparison with CA19-9. J Clin Lab Anal 1989;3:370-7.
56. Maeda I, Ku Y, Iwasaki T, et al. A case of advanced cholangiocellular carcinoma treated successfully by percutaneous isolated liver perfusion with cisplatin. Gan To Kagaku Ryoho 1996;23:1607-9. (In Japanese.)
57. Kashihara T, Ohki A, Kobayashi T, et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J Gastroenterol 1998;33: 447-53.
58. Nakao A, Taniguchi K, Inoue S, et al. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. Am J Gastroenterol 1997;92:1031-4.
59. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carry SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998;227:398-404.
60. Hedstrom J, Haglund C, Haapiainen R, Stenman UH. Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases: preferential elevation in patients with cholangiocarcinomas. Int J Cancer 1996;66:326-31.
61. Bruckner HW, Chesser MR, Mandeli J, Farber LA, DiGiovanni G. Circulating pancreatic polypeptide in patients with adenocarcinoma of the bile duct. Acta Oncol 1993;32:627-9.
62. Nakeeb A, Lipsett PA, Lillemoe KD, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996;171: 147-53.
63. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993;68:874-9.
64. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995;108:865-9.
65. Saini S. Imaging of the hepatobiliary tract. N Engl J Med 1997;336: 1889-94.
66. Hann LE, Schwartz LH, Panicek DM, Bach AM, Fong Y, Blumgart LH. Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment. Radiology 1998;206:651-6.
67. Bach AM, Loring LA, Hann LE, Illescas FF, Fong Y, Blumgart LH. Gallbladder cancer: can ultrasonography evaluate extent of disease? J Ultrasound Med 1998;17:3039.
68. Frezza EE, Mezghebe H. Gallbladder carcinoma: a 28 year experience. Int Surg 1997;82:295-300.
69. Furukawa H, Kosuge T, Shimada K, et al. Small polypoid lesions of the gallbladder: differential diagnosis and surgical indications by helical computed tomography. Arch Surg 1998;133:735-9.
70. Tillich M, Mischinger HJ, Preisegger KH, Rabl H, Szolar DH. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 1998;171:651-8.
71. Hann LE, Getrajdman GI, Brown KT, et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am J Roentgenol 1996;167:1017-21.
72. Prinz RA, Ko TC, Maltz SB, Reynes CJ, Marsan RE, Freeark RJ. Common bile duct obstruction by free floating tumor. HPB Surg 1993;6: 319-23.
73. Fulcher AS, Turner MA. HASTE MR cholangiography in the evaluation of hilar cholangiocarcinoma. AJR Am J Roentgenol 1997;169: 1501-5.
74. Schwartz LH, Coakley FV, Sun Y, Blumgart LH, Fong Y, Panicek DM. Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography. AJR Am J Roentgenol 1998; 170:1491-5.
75. Desa LA, Akosa AB, Lazzara S, Domizio P, Krausz T, Benjamin IS. Cytodiagnosis in the management of extrahepatic biliary stricture. Gut 1991;32:1188-91.
76. Mansfield JC, Griffin SM, Wadehra V, Matthewson K. A prospective evaluation of cytology from biliary strictures. Gut 1997;40:671-7.
77. Schechter MS, Doemeny JM, Johnson JO. Biliary ductal shave biopsy with use of the Simpson atherectomy catheter. J Vasc Interv Radiol 1993; 4:819-24.
78. Dooley WC, Cameron JL, Pitt HA, Lillemoe KD, Yue NC, Venbrux AC. Is preoperative angiography useful in patients with periampullary tumors? Ann Surg 1990;211:649-55.
79. Kuszyk BS, Soyer P, Bluemke DA, Fishman EK. Intrahepatic cholangiocarcinoma: the role of imaging in detection and staging. Crit Rev Diagn Imaging 1997;38:59-88.
80. Tio TL, Sie LH, Kallimanis G, et al. Staging of ampullary and pancreatic carcinoma: comparison between endosonography and surgery. Gastrointest Endosc 1996;44:706-13.
81. Wiersema MJ, Vilmann P, Giovannini M, Chang KJ, Wiersema LM. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 1997;112:1087-95.
82. Delbekc D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-6.
83. Keiding S, Hansen SB, Rasmussen HH, et al. Detection of cholangiocarcinoma in primary sclerosing cholangiris by positron emission tomography. Hepatology 1998;28:700-6.
84. Itoh A, Goto H, Naitoh Y, Hirooka Y, Furukawa T, Hayakawa T. Intraductal ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 1997;45:251-60.
85. Nimura Y, Kamiya J. Cholangioscopy. Endoscopy 1998;30:182-8.
86. Jewkes AJ, Macdonald F, Downing R, Drolc Z, Allum WH. Labelled antibody imaging in pancreatic cancer, cholangiocarcinoma, chronic pancreatitis and sclerosing cholangitis. Eur J Surg Oncol 1991;17:354-7.
87. Tan CK, Podila PV, Taylor JE, et al. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995;108:1908-16.
88. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270-6.
89. van Delden OM, de Wit LT, Nieveen van Dijkum EJ, Smits NJ, Gouma DJ, Reeders JW. Value of laparoscopic ultrasonography in staging of proximal bile duct tumors. J Ultrasound Med 1997;16:7-12.
90. Fong Y, Heffernan N, Blumgart LH. Gallbladder carcinoma discovered during laparoscopic cholecystectomy: aggressive reresection is beneficial. Cancer 1998;83:423-7.
91. Donohue JH, Nagorney DM, Grant CS, Tsushima K, Ilstrup DM, Adson MA. Carcinoma of the gallbladder: does radical resection improve outcome? Arch Surg 1990;125:237-41.
92. Ogura Y, Mizumoto R, Isaji S, Kusuda T, Matsuda S, Tabata M. Radical operations for carcinoma of the gallbladder: present status in Japan. World J Surg 1991;15:337-43.
93. Nakamura S, Nishiyama R, Yokoi Y, et al. Hepatopancreatoduodenectomy for advanced gallbladder carcinoma. Arch Surg 1994;129:625-9.
94. Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:41-7.
95. Sasaki A, Aramaki M, Kawano K, et al. Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment. Br J Surg 1998;85:1206-9.
96. Klempnaur J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 1997;79:26-34.
97. Nimura Y, Kamiya J, Nagino M, et al. Aggressive surgical treatment of hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 1998;5:52-61.
98. Sakamoto E, Nimura Y, Hayakawa N, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg 1998;227:405-11.
99. Bartlett D, Fong Y, Blumgart LH. Complete resection of the caudate lobe of the liver: technique and results. Br J Surg 1996;83:1076-81.
100. Nagino M, Nimura Y, Kamiya J, et al. Segmental liver resections for hilar cholangiocarcinoma. Hepatogastroenterology 1998;45:7-13.
101. Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998;227:70-9.
102. Reding R, Buard JL, Lebeau G, Launois B. Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded): results of the French Surgical Association Survey. Ann Surg 1991;213:236-41.
103. Monson JR, Donohue JH, McEntee GP, et al. Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991;126:353-7.
104. Fong Y, Blumgart LH, Lin E, Former JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg 1996;83:1712-5.
105. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998;227:821-31.
106. Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998;187:358-64.
107. Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44:121-6.
108. Goldstein RM, Stone M, Tillery GW, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993;166:768-72.
109. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis: a 12-year single center experience. Ann Surg 1997;225:472-83.
110. Nordback IH, Pitt HA, Coleman J, et al. Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation. Surgery 1994;115: 597-603.
111. Taschieri AM, Elli M, Danelli PG, Cristaldi M, Montecamozzo G, Porretta T. Third segment cholangio-jejunostomy in the treatment of unresectable Klatskin tumors. Hepatogastroenterology 1995;42:597-600.
112. Jarnagin WR, Burke E, Powers C, Fong Y, Blumgart LH. Intrahepatic biliary enteric bypass provides effective palliation in selected patients with malignant obstruction at the hepatic duct confluence. Am J Surg 1998;175:453-60.
113. Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997;39:929-35.
114. Gonzalez Gonzalez D, Gerard JP, Maners AW, et al. Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor). Semin Liver Dis 1990;10:131-41.
115. Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994;28:945-51.
116. Kuvshinoff BW, Armstrong JG, Fong Y, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 1995;82:1522-5.
117. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221: 788-98.
118. Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996;39:852-5.
119. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998;82: 2321-5.
120. Prat F, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 1998;42:76-80.
121. Schima W, Prokesch R, Osterreicher C, et al. Biliary Wallstent endoprosthesis in malignant hilar obstruction: long-term results with regard to the type of obstruction. Clin Radiol 1997;52:213-9.
122. Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-42.
123. de Groen PC, Barry JA, Schaller WJ. Applying World Wide Web technology to the study of patients with rare diseases. Ann Intern Med 1998;129:107-13.
124. Johlin FC, Voigt M, Wu YM. Surveillance cytology (SC) in the detection of asymptomatic progression to cholangiocarcinoma (CCC) in patients with primary sclerosing cholangitis. Hepatology 1998;28:Suppl: 393A. abstract.
125. Ito R, Tamura K, Ashida H, et al. Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. Int J Oncol 1998;12: 1019-23.
126. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.